NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INSPDecember 01, 2025 4:03 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - December 1, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the " ...

INSP SHAREHOLDERS: Inspire Medical Systems, Inc. Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by January 5December 01, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 1, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud ...

Core Viewpoint - Inspire Medical Systems, Inc. is facing a securities class action lawsuit due to allegations of misleading investors regarding the launch of its Inspire V device for obstructive sleep apnea, which resulted in a significant decline in stock price [1][3]. Group 1: Lawsuit Details - The lawsuit, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., targets the company and its executives, representing investors who acquired stock between August 6, 2024, and August 4, 2025 [3]. - The complaint alleges violations of the Securities Exchange Act of 1934, claiming that management made false statements about the successful launch of the Inspire V device [3][7]. Group 2: Allegations Against Inspire Medical - The lawsuit claims that the transition to the Inspire V device was not seamless as promised, citing operational failures that hindered the launch [4]. - Key allegations include poor market demand due to existing inventory of the previous device, incomplete readiness for the rollout, and undisclosed logistical issues that affected billing and operational processes [10]. Group 3: Market Reaction - On August 4, 2025, Inspire Medical admitted to an "elongated timeframe" for the Inspire V launch, leading to a drastic reduction in 2025 earnings guidance by over 80% [5][6]. - Following this announcement, the company's stock price plummeted by over 32% on heavy trading volume, prompting the investor class action [6]. Group 4: Investigation Focus - Hagens Berman is investigating the claims against Inspire Medical, particularly focusing on potential misstatements or omissions related to the Inspire V launch and its financial implications [11]. - The investigation aims to determine if management was aware of critical operational flaws before the public disclosure on August 4 [12].

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Inspire Medical Systems and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case, which is pending in the U.S. District Court for the District of Minnesota [3]. Group 2: Company Background - Inspire Medical Systems develops an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Allegations and Stock Impact - The lawsuit alleges that Inspire misled investors by claiming it had taken necessary steps for the launch of Inspire V, while in reality, it failed to prepare clinicians and payors, leading to delays and weak demand [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, causing the stock price to drop by $42.04, or more than 32%, from $129.95 to $87.91 per share [7][8].

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

Core Insights - Inspire Medical Systems, Inc. is facing a class action lawsuit for allegedly misleading investors regarding the launch of its Inspire V Device, which was anticipated to significantly increase revenue [1][5] - The lawsuit highlights operational failures, including insufficient training for treatment centers and IT system issues, leading to a more than 80% reduction in the company's 2025 earnings guidance [2][5] - Following the earnings guidance cut, the stock price plummeted over 32%, resulting in a loss of $1.2 billion in market capitalization [2] Financial Performance - The company's stock has shown considerable volatility, with a 52-week high of $216.01 and a low of $70.77 [4] - As of the latest trading, the stock is priced at $125.22, despite a recent decrease of 1.66%, equating to a $2.11 drop [3][5] - Wolfe Research upgraded Inspire's stock to "Outperform" on November 25, 2025, indicating potential for recovery [3][5] Market Position - Inspire Medical Systems has a current market capitalization of approximately $3.71 billion, with a trading volume of 508,655 shares [4] - Shareholders interested in the class action lawsuit must submit their papers by January 5, 2026, with Robbins LLP managing the case on a contingency fee basis [4]

INSP CLASS REMINDER: Inspire Medical Systems, Inc. Investors with Losses are Reminded to Contact BFA Law before the Imminent January 5 Securities Class Action DeadlineNovember 28, 2025 8:18 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 28, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for ...

Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the lawsuit is from August 6, 2024, to August 4, 2025, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - A class action lawsuit has already been filed, and investors wishing to serve as lead plaintiffs must act by January 5, 2026 [4][8]. Group 2: Allegations Against Inspire Medical - The lawsuit alleges that Inspire Medical misrepresented and failed to disclose critical information regarding the Inspire V sleep apnea device, including actual market demand and necessary steps for its launch [6]. - Defendants are accused of issuing materially false and misleading statements that led investors to believe in strong demand for the Inspire V device, resulting in investor damages when the truth was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [5]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has consistently ranked in the top 4 for securities class action settlements since 2013 [5].